EGFR and glioblastoma: Parrozzani et al. were the first to prospectively analyze, using CCM, corneal side effects induced by depatuxizumab mafodotin (ABT-414), an EGFR inhibitor, in a group of patients affected by EGFR-amplified recurrent glioblastoma [28,39].